arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

EyePoint, Inc.

EYPT
$12.81 ▲ +0.58 (+4.78%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

EyePoint, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -27.5%
Op. Margin None
ROIC -79.6%
FCF / Share None
Trailing P/E
Price / Book 3.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.37M
↓ -27.5%
Net Income Profit after all expenses
$-231.96M
↓ -77.2%
Operating Margin Operating profit as % of sales
-337.1%
↓ -106.6%
FCF / Share Free cash flow per share
$-0.04
↑ +97.7%
Long-Term Debt Long-term obligations
$30.00M
↓ -17.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 65 quarters